6-PURINYL N-(2-CHLOROETHYL) CARBAMATE AND THIOCARBAMATE, A PROCESS FOR THEIR PREPARATION AND USE THEREOF

Abstract: The invention relates to 6-purinyl N-(2-chloroethyl) carbamate and thiocarbamate of the general formula I in which X stands for an oxygen or sulphur atom, and to a process for their preparation by reacting a purine derivative of the general formula II (hypoxanthine or 6-mercaptopurine, respectively) with 2-chloroethylisocyanate. The compounds of formula I show a remarkable antineoplastic effect in vitro and in vivo , and consequently provide a potential treatment for malignant neoplastic diseases in mammals.

Description: The invention relates to 6-purinyl N-(2-chloroethyl) carbamate and thiocarbamate of the general formula I in which X stands for an oxygen or a sulphur atom, and to a process for the preparation thereof. The pertinent literature reports certain 6-purinyl derivatives of carbamic acid, eg N-(6-purinyl)-N'-aryl-and N'-alkylureas [A S Jones et al, Tetrahedron 26 , 791 (1970); H Griengl et al, Arch Pharm 317 (3), 193 (1984)] and N-(2-chloroethyl)-6-aminopurine-9-carboxide formed by reacting 2-chloroethylisocyanate with adenine [Miyahara Michiko et al, Eisai Shikenako Hokoku 1980 (98), 123-5; Chem Abstr 94 , 114381w (1981)]. The named compounds did not exhibit any biological activity with the exception of some adenine urea derivatives, eg N-(6-purinyl)-N',N'-diethylurea, which showed a weak antineoplastic (antineoplasmic) action. The compounds of the present invention, 6-purinyl esters of N-(2-chloroethyl) carbamic acid, represent a new previously undescribed class of compounds which surprisingly showed a remarkable antineoplastic activity in vitro and in vivo . The subject compounds of formula I can be prepared by reacting the respective 6-substituted purine derivative of the general formula II in which X has the above defined meaning, with 2-chloro-ethylisocyanate formula III Cl-CH₂-CH₂-N=C=O (III) in an inert medium at a temperature substantially within a range of from 0 to 50°C, preferably in the presence of an alkaline agent. The starting purine derivatives of formula II, ie hypoxanthine (X = 0) and 6-mercaptopurine (X = S), are commercially available materials. The preparation of 2-chloroethylisocyanate is described at several places in the literature [cf eg Siefken W, Ann Chem 562 , 103 (1949)]. Suitable inert media for the aforementioned reaction are advantageously dimethylformamide, dimethylsulfoxide, phosphoric acid hexamethyltriamide or tetramethylurea. The reaction of hypoxanthine or 6-mercaptopurine with 2-chloroethylisocyanate proceeds rather slowly; yet, surprisingly, it is unexpectedly accelerated in the presence of one to two molar equivalents of an alkaline agent, preferably a tertiary organic amine such as, eg triethylamine, diisopropylethylamine, 1-ethylpiperidine, 4-methylmorpholine or the like, whereby the reaction rate is approx by an order of magnitude increased and also the yield of the desired product is substantially higher. The compounds of the invention are either slightly soluble in the aforementioned solvents and separate spontaneously from these media during the reaction, or can easily be isolated from the reaction mixture by dilution with water and subsequent filtration. The subject compounds of the general formula I, ie 6-[N-(2-chloroethyl) carbamoyl] thiopurine (compound Ia, X = S) and its oxygen analogue, 6-N-[(2-chloroethyl) carbamoyl] oxypurine (compound Ib, X = 0), show a remarkable antineoplastic activity in pharmacological experiments both in vitro and in vivo in experimental animals and consequently have a potential for the treatment of malignant neoplastic diseases of biological objects, especially of mammalia origin, when administered either alone or in combination with other agents having an antineoplastic activity. The antineoplastic activity of the compounds of the invention has been investigated testing the compounds of the chemical group " in vivo " against experimental rodent tumours such as Crocker's sarcoma (S180), solid-type Ehrlich sarcoma (STE), Kreb's ascites tumour (Kr2), all maintained in mice H, Gardner lymphosarcoma (LsG, C3H mice), P388 and L1210 leukaemia (DBA2 mice), Zajdela ascites hepatoma (ZAH, Wistar rats), Yoshida ascites reticulosarcoma (Y, Wistar rats) and B16 melanoma (C57B16 mice) in experiments according to Jelinek, V [Neoplasma 12 , 469 (1969); ibid 7 , 146 (1960)] and " in vitro " experiments using radioactive precursors of nucleic acids and proteins according to Miko, M et al [Cancer Res 39 , 4242 (1979); Neoplasma 26 , 449 (1979); ibid 16 , 161 (1969)] with minor modifications [Mattern J: Studies on the Drug Sensitivity of Short Term Cultured Tumour Cell Suspensions. In "Human Tumours in Short Term Culture" (Dendy, P P ed), p 301, Academic Press 1976]. Therapeutic synergism has been studied by the method of Carter, W H et al [cf Cancer Res 42 , 2963 (1982)]. The therapeutic effect for the purposes of the invention means the inhibition of characteristic disease symptoms in biological subjects bearing tumours which are namely tumour growth, shortening of the survival period of biological subject and increasing the number or the growth of tumour cells. Tumour growth may be observed clinically or in experiments in vivo , that is, with experimental animals, or in vitro , for example, in tissue cultures prepared from tumours. The assessment of tumour growth may be effected by measuring the weight of the tumour mass or, more effectively, by measuring the radioactivity after incorporation therein of certain substances of natural origin such as amino acids (for example, valine), nucleic bases or the like (thymidine etc) labelled with radioactive atoms such as ¹⁴C, ³H, etc. Such a useful therapeutical effect of the compounds of the present invention has been proved in experiments with S180 and/or STE tumour bearing female mice H. In comparison with untreated control animals significantly lower mean tumour weights have been observed in treated groups of animals (cf examples 3 and 4). Additionally, the compounds of the present invention are useful in increasing survival time of the suitable biological subjects, namely mice and rats bearing tumours STE, ZAH and/or Y; because the lethal nature of the test system employed, the antitumour effect of the compounds is illustrated by a side-by-side comparison of the survival time of treated animals (those which survived for a longer time) with the untreated control groups of animals (cf examples 5, 6, 7). In these typical experiments ten animals were in the experimental groups and the treated groups of animals survived for a longer time than the untreated controls. Moreover, in some cases the antitumour effect of the compounds of the present invention has been proven in experimental conditions in which the clinically useful and structurally similar compound 6-mercaptopurine was inactive (cf example 8). The result of the experiment is in agreement with the idea that mechanism of action of the compound Ia is different from that of clinically used 6-mercaptopurine. This effect may be clinically useful in all cases of the resistance of the tumour or leukaemia against an antimetabolite of this class. Additionally, the therapeutic synergism of the compounds of the general formula I with other cytostatic drugs has been proven, for example, in combination chemotherapy with Benfluron (5-[2-(N,N-Dimethylamino) ethoxy]-7-oxo-7H-benzo(c)fluorene hydrochloride - CAS 80427-58-3) - cf example 9. The groups of animals treated by combination of the compound Ia with the cytostatic drug Benfluron survived for a highly significant longer time (p ≦ 0.01) than the untreated animals of the control group or animals treated with Benfluron alone. The foregoing examples indicate that the compound Ia may be effectively used alone or in combination with other cytostatic drugs for treatment of malignant neoplastic diseases. In experiments in vivo with Ehrlich ascites carcinoma cells and/or Yoshida ascites tumour cells, the compound Ia has been more effective than some clinically used drugs, namely thioguanine (2-Amino-6-mercaptopurine, NSC 752) and/or 6-mercaptopurine (NSC 755), cf examples 10 and 11. The compounds of the present invention are also potent inhibitors of DNA and protein biosyntheses of tumour cells. This conclusion clearly followed from example 12. Inhibition of any of the vital biosynthesis mentioned above is attainable as a result of antitumour activity of cytostatic drugs. The compounds described herein can be administered to suitable biological subjects, particularly mammals, for their therapeutic antitumour effects by conventional modes of administration alone, but preferably as active ingredients with any conventional suitable non-toxic pharmaceutical carrier, dissolved or suspended, for example, in water, saline, polyethylene or polypropylene alcohols, etc. The administration is preferably by the oral route. The dosage administered will be dependent upon the type of tumour for which treatment is desired, the type of biological subject involved, weight, body surface, localisation to the tumour, its morphological type, the frequency of treatment, individual tolerance and responsiveness of each subject, etc; for example, by oral route, the prolonged administration of 100, 200 mg/kg daily appears to be well tolerated both in the rat and in the mouse. The assessment drawn from the biological tests is that doses of 20 mg/kg (eg, about 740 mg/m²) could be regarded as well tolerated in man. The compounds are hardly toxic; for example, the compound Ia is practically non-toxic (the LD₅₀ in small rodents was assessed up to 3 g/kg by oral route). It is understood that therapeutically useful effects can be expected to occur upon the administration of such doses that are completely non-toxic to the respective mammalian organism. The process for preparing the subject compounds of formula I as well as their selected biological assay results are illustrated by the subsequent non-limitative examples. Melting points were determined on Kofler block and are not corrected, yields are indicated in stoichiometric % of theory. Example 1 6-[N-(2-Chloroethyl) carbamoyl] thiopurine (Ia). A suspension of 6-mercaptopurine monohydrate (17. 0 g, 0. 1 mole) in dimethylformamide (150 ml) is treated with triethylamine (10.1 g, 0.1 mole) and the solid is dissolved by warming of the mixture to 50 - 60°C. The solution is cooled to 15°C and 2-chloroethylisocyanate (11.6 g, 0.11 mole) is dropped in under cooling with tap water to 15 - 20°C. The reaction mixture is stirred at this temperature for 2 hours, and the precipitated product is collected on filter, washed with acetone and dried under reduced pressure at a temperature of approx 50°C to give 20.7 g (80%) of the title compound Ia melting at 221 - 223°C. UV absorption spectrum (in dimethylsulfoxide), λ max 326 nm (logε 4.33). Example 2 6-[N-(2-Chloroethyl) carbamoyl] oxypurine (Ib). To a suspension of hypoxanthine (6.8 g, 50 mmoles) in dimethylformamide (200 ml) there is added triethylamine (5.05 g, 50 mmoles) and then, at 15 - 20°C, 2-chloroethylisocyanate (5.8 g, 55 mmoles) is dropped in. The reaction mixture is stirred at this temperature until dissolution of the solid (approx for 2 hours), thereafter poured into an ice-water mixture (750 ml), the precipitate of the title product is separated by suction, washed with acetone and dried at room temperature. The yield is 8.2 g (67.8%) of compound Ib, mp 320 - 340°C (with decomposition), UV absorption spectrum (in dimethylsulfoxide), λ max 275 nm (logε 3.76). Example 3 An illustration of the antitumour activity of the substance Ia. Sixty female mice H weighing approximately 20 g were divided into three groups: one control group and two experimental groups of 20 animals each. A lethal dose of the Crocker tumour (S180) homogenate was implanted subcutaneously to all the animals. The experimental groups were treated with the substance Ia in water suspension. The suspension contained the substance Ia in such an amount that a dose 0.4 or 0.2 ml of the suspension po was equal to a dose 200 or 100 mg Ia/kg. This dose was administered to the experimental animals once a day, eight times altogether, starting on the fifth day after the implantation. On the fourteenth day after the implantation, half of the animals in each group were killed by ether anaesthesia, tumours were removed and weighed. The remaining animals were left to monitor the time of death. Statistically, significantly lower average values of the tumour weight were observed in the treated animals in comparison with the untreated control group. Example 4 An illustration of the antitumour activity of the substances Ia and Ib. In analogous experiments carried out on the animals with implanted Ehrlich tumour (STE) (female mice H weighing approximately 20 g, 20 animals per group) the treated animals exhibited statistically significantly lower average values of the tumour weight in comparison with the untreated control group. The results of the experiments are summarized in the following table. Substance Administration Dose (mg/kg) Tumour weight (% of control) Ia po 8 x 200 70 8 x 100 80 Ib po 8 x 200 81 8 x 100 76 Example 5 An illustration of the therapeutic effect of the substance Ia. Fifty infantile female Wistar rats weighing approximately 60 g were divided into five groups: one control and four experimental ones, 10 animals in each. A lethal dose of the tumour ascites from Zajdel ascitic hepatoma was implanted intraperitoneally to all the animals. The experimental groups were treated with the substance Ia in water suspension. The suspension contained the substance Ia in such an amount that a dose of 0.4 or 0.2 ml of the suspension po was equal to a dose of 200 or 100 mg Ia/kg. This dose was administered to the experimental animals once a day, five times altogether, starting on the first day after implantation. The results are summarized in the following table. Substance Administration Dose (mg/kg) Period of survival (% of control) Ia po 5 x 200 126 5 x 100 117 Example 6 An illustration of the therapeutic effect of the substances Ia and Ib in comparison with 6-mercaptopurine (NSC 755). As in Example 5 an experiment was performed in an analogous fashion upon animals with implanted Yoshida tumour (infantile female Wistar rats weighing approximately 60 g, 10 animals per group) and resulted in a statistically significantly higher average value of the survival period in the treated animals in comparison with the untreated control group. The results of the experiment are summarized in the following table. Example 7 An illustration of the therapeutic effect of the substance Ia in comparison with 6-mercaptopurine (NSC 755). As for examples 5 and 6 an experiment was performed in an analogous fashion upon animals with implanted Yoshida tumour (infantile female Wistar rats weighing approximately 60 g, 10 animals per group) showed a statistically significantly higher average value of the survival period in the treated animals in comparison with the untreated control group. The results of the experiment are summarized in the following table. Substance Administration Dose (mg/kg) Period of survival (% of control) 6-mercaptopurine po 5 x 40 156 5 x 20 107 Ia po 5 x 200 158 5 x 100 124 Example 8 An illustration of the therapeutic effect of the substance Ia in an experiment in which a distantly similar 6-mercaptopurine proved ineffective. An experiment analogous to those of examples 5 to 7 performed in animals with implanted Zajdel ascitic hepatoma (infantile female Wistar rats weighing approximately 60 g, 10 animals per group) showed a statistically significantly higher average period of survival in the animals treated with the substance Ia but not in those treated with 6-mercaptopurine, in comparison with the untreated control group. The results of the experiment are summarized in the following table. Substance Administration Dose (mg/kg) Period of survival (% of control) 6-mercaptopurine po 5 x 40 105 5 x 20 101 Ia po 5 x 200 128 5 x 100 120 Example 9 An illustration of the therapeutic synergism of the substance Ia with other cytostatic drugs. One hundred and twenty seven infantile female Wistar rats weighing 50 - 60 g were divided into 16 groups: one control group of 25 animals and fifteen experimental groups of 6 to 7 animals. A lethal dose of the tumour ascites from Yoshida ascitic sarcoma was implanted intraperitoneally to all the animals. The experimental groups were treated with the substance Ia in water suspension, water solution of a cytostatic Benfluron (CAS 80427-58-3), or a combination of both the substances. The suspension or solution contained the substances in such a concentration that doses 0.4 or 0.2 and 0.1 ml of the suspension/ solution po were equal to doses 200 or 100 and 50 mg Ia/kg or to doses 160, 80 or 40 mg Benfluron/kg. Doses of the substance Ia were administered to the experimental animals once a day, four times altogether, starting on the first day after the tumour implantation. Benfluron was administered only once, on the fourth day after the tumour implantation, 7 hours after the last dose of the substance Ia. Over a period of 29 days it was observed that all the animals in the control group died on the fifth to the fifteenth days after the implantation while the groups treated With the substance Ia or with its combination with the cytostatic Benfluron survived longer with an average statistical significance (α = 0.05) or a high statistical significance (α = 0.01). The results of the experiment are summarized in the following table. Fiducial limits of the geometric average for P = 1-α = 0.95 are given in parentheses. Example 10 Cytotoxicity of the substance Ia in vitro in comparison with 2-amino-6-mercaptopurine (NSC 752). The degree of influence on the incorporation of ¹⁴C from adenine-¹⁴C and valine-¹⁴C to the fraction of Ehrlich Carcinoma cells insoluble in trichloroacetic acid serves as the measure of cytotoxicity. The value ID₅₀ is the concentration of a cytostatic that reduces the ¹⁴C incorporation down to 50% of the non-influenced control cells. The results of the experiment are summarized in the following table. Substance Precursor ID₅₀ (µmol/1) Ia adenine-¹⁴C 94 valine-¹⁴C 155 2-amino-6-mercaptopurine adenine-¹⁴C 600 valine-¹⁴C 600 Example 11 Cytotoxicity of the substance Ia in vitro in comparison with 6-mercaptopurine (NSC 755). In analogous experiments to those already described the degree of influence on the initial velocity of the incorporation of ³H from 5-iodo-2'-deoxy-(6-³H) uridine or that of ¹⁴C from a mixture of L-(U-¹⁴C)aminoacids to the fraction of Yoshida ascitic tumour cells insoluble in trichloroacetic acid serves as the measure of cytotoxicity. The values IC₅₀ is the concentration of a substance that reduces the initial velocity of the ³H or ¹⁴C incorporation down to 50% of the non-influenced control cells. The results are summarized in the following table. Substance Precursor IC₅₀ (µmol/1) 6-mercaptopurine 5-iodo-2'-deoxy(6-³H)uridine 10000 L-(U-¹⁴C)aminoacids 229 Ia 5-iodo-2'-deoxy(6-³H)uridine 25 L-(U-¹⁴C)aminoacids 26 Example 12 Comparison of the cytotoxicity of the substance Ia and Ib in vitro . In analogous experiments to those described above the following values of IC₅₀ were determined. Substance Precursor IC₅₀ (umol/1) Fiducial limits (P = 0.95) Ia 5-iodo-2'-deoxy(6-³H)uridine 39 (21; 106) Ib 5-iodo-2'-deoxy(6-³H)uridine 55 (47; 65) Ia L-(U-¹⁴C)aminoacids 62 (24; 8.10³) Ib L-(U-¹⁴C)aminoacids 80 (66; 104)

Claims: 6-Purinyl N-(2-chloroethyl) carbamate and thiocarbamate of the general formula I wherein X stands for an oxygen or a sulphur atom. 6-[N-(2-Chloroethyl) carbamoyl] oxypurine. 6-[N-(2-Chloroethyl) carbamoyl] thiopurine. An antineoplastic composition comprising a therapeutically effective amount of 6-purinyl N-(2-chloroethyl) carbamate and/or thiocarbamate of the general formula I wherein X stands for an oxygen atom or a sulphur atom and a pharmaceutically acceptable carrier, excipient or diluent. 6-Purinyl N-(2-chloroethyl) carbamate and thiocarbamate of the general formula I wherein X stands for an oxygen or a sulphur atom for use in the treatment of malignant neoplastic diseases in mammals. The use of 6-Purinyl N-(2-chloroethyl) carbamate and thiocarbamate of the general formula I for the manufacture of a medicament for the treatment of malignant neoplastic diseases in mammals. A process for the preparation of 6-purinyl N-(2-chloroethyl) carbamate and thiocarbamate of the general formula I, in which X stands for an oxygen or a sulphur atom, comprising reacting the respective 6-substituted purine derivative of the general formula II in which X has the same meaning as in formula I, with 2-chloroethylisocyanate of formula III Cl-CH₂-CH₂-N=C=O (III) in an inert medium at a temperature substantially within a range of from 0 - 50°C, preferably in the presence of an alkaline agent. A process according to claim 7 characterized in that a tertiary organic amine such as, eg triethylamine, diisopropylethylamine, 1-ethylpiperidine or 4-methylmorpholine is used as the alkaline agent. 6-[N-(2-Chloroethyl) carbamoyl] oxypurine whenever prepared by a process substantially in accordance with either of the preceding claims 7 or 8 or an obvious equivalent thereof. 6-[N-(2-Chloroethyl) carbamoyl] thiopurine whenever prepared by a process substantially in accordance with either of the preceding claims 7 or 8 or an obvious equivalent thereof.

Inventors: BEITOVA, MARTA, CERNY, ANTONIN, RNDR. CSC, GRIMOVA, JAROSLAVA, MUDR. CSC., KEJHOVA, IRENA, KREPELKA, JIRI ING. CSC, MELKA, MILAN, MUDR. RNDR., MILKO, MILAN, DOC. ING. CSC., POKORNA, STANISLAVA, REICHLOVA, RUZENA, Beitová, Marta, Grimová, Jaroslava, MUDr. CSc., Kejhová, Irena , Pokorná, Stanislava, Reichlová, Ruzena
Applicants: SPOFA  SPOJENE PODNIKY PRO ZDRAVOTNICKOU VYROBU
Application year: 1985
Main classification: C07D473
IPC codes: C07D473, A61P35, A61K31